Expertise in
6
conditions

Dr. Hassan M. Alnuaimat

Anesthesiology | Pulmonary Medicine
1600 Sw Archer Road, 
Gainesville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
1600 Sw Archer Road, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hassan Alnuaimat is an Anesthesiologist and a Pulmonary Medicine provider in Gainesville, Florida. Dr. Alnuaimat is highly rated in 6 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Endoscopy.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Anesthesiology
Pulmonary Medicine
Licenses
Anesthesiology in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

1600 Sw Archer Road, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 10 Less Clinical Trials

44 Total Publications

Serpiginous-Like Choroiditis with ANCA-PR3 Vasculitis in a Patient from Endemic Country: A Complex Phenotypic, Immunological and Epidemiological Puzzle.
Serpiginous-Like Choroiditis with ANCA-PR3 Vasculitis in a Patient from Endemic Country: A Complex Phenotypic, Immunological and Epidemiological Puzzle.
Journal: Ocular immunology and inflammation
Published: December 10, 2024
Similar Doctors
Hiren J. Mehta
Expertise in
28
conditions
Dr. Hiren J. Mehta
Pulmonary Medicine | Intensive Care Medicine
Expertise in
28
conditions
Dr. Hiren J. Mehta
Pulmonary Medicine | Intensive Care Medicine

Florida Clinical Practice Association Inc

2001 Sw 13th St, Gi Clinic At Endoscopy Center, 
Gainesville, FL 
 (0.5 mi)
352-265-8982
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hiren Mehta is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Gainesville, Florida. Dr. Mehta is highly rated in 28 conditions, according to our data. His top areas of expertise are Lung Nodules, Lung Cancer, Pleural Effusion, Endoscopy, and Gastrostomy. Dr. Mehta is currently accepting new patients.

Expertise in
5
conditions
Dr. Mark L. Brantly
Pulmonary Medicine
Expertise in
5
conditions
Dr. Mark L. Brantly
Pulmonary Medicine
1600 Sw Archer Rd, 
Gainesville, FL 
 (0.1 mi)
352-273-8737
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Brantly is a Pulmonary Medicine provider in Gainesville, Florida. Dr. Brantly is highly rated in 5 conditions, according to our data. His top areas of expertise are Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), Subcutaneous Emphysema, Lymphangioleiomyomatosis, and Lung Transplant. Dr. Brantly is currently accepting new patients.

Expertise in
12
conditions
Dr. Borna Mehrad
Pulmonary Medicine
Expertise in
12
conditions
Dr. Borna Mehrad
Pulmonary Medicine

Florida Clinical Practice Association Inc

1600 Sw Archer Rd, Suite 100371, 
Gainesville, FL 
 (0.1 mi)
Languages Spoken:
English

Borna Mehrad is a Pulmonary Medicine provider in Gainesville, Florida. Dr. Mehrad is highly rated in 12 conditions, according to our data. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pneumonia, Lung Transplant, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alnuaimat's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile